

## Combined Shareholders' Meeting of 30 May 2018

### Availability and consultation of preparatory documents for the Shareholders' Meeting

**Paris (France), 9 May 2018** – The Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 30 May 2018 at 3 pm (Paris time) at the Maison des Arts et Métiers (salon La Rochefoucauld), 9 bis avenue d'Iéna, 75116 Paris, France.

The preliminary notice of meeting was published in the *Bulletin des Annonces Légales Obligatoires* (BALO) of 20 April 2018 and the notice of meeting in the BALO of 9 May 2018. These documents, as well as the Convening notice (including, in particular, the agenda, the proposed resolutions and the conditions regarding attendance and vote), are also available on Ipsen's website at the following address: [www.ipsen.com](http://www.ipsen.com), under the "Investors/Shareholders' meetings" section.

Documents and information relating to this Meeting will be made available to shareholders under the legal and regulatory conditions in force.

In accordance with applicable regulatory provisions:

- Registered shareholders may, up to the fifth day (inclusive) before the Meeting, request from the Company to send these documents, where appropriate at his/her express request by electronic means. For holders of bearer shares, the exercise of this right is subject to the presentation of a shareholding certificate (*attestation de participation*) in the bearer securities accounts managed by the authorized intermediary.
- Any shareholder may consult these documents at the Company's headquarters.

#### About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit [www.ipsen.com](http://www.ipsen.com).

#### For further information:

##### Media

###### Ian Weatherhead

Vice President, Corporate External Communications  
+44 (0) 1753 627733  
[ian.weatherhead@ipsen.com](mailto:ian.weatherhead@ipsen.com)

###### Brigitte Le Guennec

Senior Manager, Global External Communications  
+33 (0)1 58 33 51 17  
[brigitte.le.guennec@ipsen.com](mailto:brigitte.le.guennec@ipsen.com)

##### Financial Community

###### Eugenia Litz

Vice President, Investor Relations  
+44 (0) 1753 627721  
[eugenia.litz@ipsen.com](mailto:eugenia.litz@ipsen.com)

###### Myriam Koutchinsky

Investor Relations Manager  
+33 (0)1 58 33 51 04  
[myriam.koutchinsky@ipsen.com](mailto:myriam.koutchinsky@ipsen.com)